| |
| |
|
| Insider
Information: |
Soni Manmeet Singh |
| Relationship: |
Chief Operating Office... |
| City: |
Sunnyvale |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
2,982,092 |
|
|
Indirect Shares
|
83 |
|
|
| Direct
Value |
$11,125,854 |
|
|
|
Indirect Value
|
$12,178 |
|
|
| Total
Shares |
2,982,175 |
|
|
| Total
Value |
$11,138,031 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
7
|
|
Stock
price went up :
|
1
|
7
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
7.0
|
| Percentage
Gain/Loss : |
 38.9%
|
539.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pharmacyclics Inc |
PCYC |
Chief Financial Officer |
2015-05-26 |
0 |
2013-04-30 |
0 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Chief Financial Officer |
2017-07-25 |
0 |
2018-07-10 |
83 |
Premium* |
|
|
Arena Pharmaceuticals Inc |
ARNA |
Director |
2020-06-17 |
5,902 |
2018-12-14 |
0 |
Premium* |
|
|
Reata Pharmaceuticals Inc |
RETA |
COO, CFO and President |
2023-09-26 |
0 |
2020-08-14 |
0 |
Premium* |
|
|
Summit Therapeutics Inc |
SMMT |
Chief Operating Office... |
2023-10-13 |
2,976,190 |
2023-10-13 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SMMT |
Summit Therapeutics Inc |
Chief Operating Officer |
• • – |
2023-10-13 |
4 |
B |
$1.68 |
$4,999,999 |
D/D |
2,976,190 |
2,976,190 |
2.81 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(62,621) |
0 |
0 |
- |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-08-16 |
4 |
S |
$168.41 |
$295,566 |
D/D |
(1,755) |
62,621 |
0 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-07-28 |
4 |
AS |
$164.62 |
$12,346,298 |
D/D |
(75,000) |
64,376 |
0 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
139,376 |
0 |
- |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
64,376 |
0 |
- |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-06-13 |
4 |
S |
$99.75 |
$8,034,343 |
D/D |
(78,085) |
58,376 |
0 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-06-13 |
4 |
OE |
$27.32 |
$683,000 |
D/D |
25,000 |
136,461 |
0 |
- |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-06-12 |
4 |
S |
$99.62 |
$469,297 |
D/D |
(4,711) |
111,461 |
0 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-05-16 |
4 |
S |
$80.93 |
$50,584 |
D/D |
(625) |
116,172 |
0 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-05-15 |
4 |
S |
$84.32 |
$1,818,567 |
D/D |
(21,507) |
116,797 |
0 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
138,304 |
0 |
- |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-03-07 |
4 |
S |
$84.70 |
$52,680 |
D/D |
(622) |
88,304 |
0 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-03-03 |
4 |
S |
$87.97 |
$315,548 |
D/D |
(3,587) |
88,926 |
0 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO, CFO and President |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
23,513 |
92,513 |
0 |
- |
|
| RETA |
Reata Pharmaceuticals Inc |
COO and CFO |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
69,000 |
0 |
- |
|
| RETA |
Reata Pharmaceuticals Inc |
COO and CFO |
• – – |
2021-12-31 |
4 |
B |
$26.22 |
$419,565 |
D/D |
16,000 |
19,000 |
2.74 |
% |
|
| RETA |
Reata Pharmaceuticals Inc |
COO and CFO |
• – – |
2020-08-14 |
4 |
B |
$100.19 |
$300,630 |
D/D |
3,000 |
3,000 |
2.74 |
% |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2020-06-17 |
4 |
AS |
$62.74 |
$19,073 |
D/D |
(304) |
5,902 |
0 |
% |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2020-06-15 |
4 |
AS |
$60.12 |
$79,779 |
D/D |
(1,327) |
6,206 |
0 |
% |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,446 |
7,533 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2019-06-14 |
4 |
AS |
$55.82 |
$68,022 |
D/D |
(1,217) |
5,087 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,654 |
6,304 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,650 |
1,825 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2018-07-10 |
4 |
A |
$0.00 |
$0 |
I/I |
36 |
83 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
